Business Context and Reporting Period
This Form 8-K reports the results of the 2024 Annual Meeting of Shareholders held by Collegium Pharmaceutical, Inc. on May 16, 2024. The record date for the meeting was March 27, 2024.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
A total of 32,705,747 shares were entitled to vote, with 31,059,529 shares present in person or by proxy. The following matters were approved:
- Proposal 1 (Election of Directors): All eight nominees were re-elected to serve until the 2025 Annual Meeting. Notable voting statistics include:
- Rita Balice-Gordon: 28,105,388 For; 568,305 Against.
- John Fallon: 25,399,411 For; 3,273,949 Against (highest "Against" vote count).
- Michael Heffernan: 26,121,329 For; 2,552,363 Against.
- Proposal 2 (Executive Compensation): Shareholders approved the advisory vote on named executive officer compensation with 28,311,783 votes For and 350,755 votes Against.
- Proposal 3 (Auditor Ratification): Shareholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, with 30,106,217 votes For and 92,255 votes Against.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the specific reasons for the higher "Against" votes for directors John Fallon and Michael Heffernan compared to other nominees.
- Confirm the total number of broker non-votes (2,360,841 for director elections) to understand the impact on quorum and voting power.
- Review the company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.